Vancouver-based company SaNOtize, co-founded by Israeli-Canadian scientist Dr. Gilly Regev, is launching its first clinical trial in the UK this week for a proposed antiviral nasal spray for use against COVID-19.

The tests will begin on Monday at Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey and will be overseen by Rob Wilson, a former British government minister who represents SaNOtize in the UK and EU, the company announced in a statement Sunday.